Deals channel feed – Endpoints News

Deals channel feed

Gilead’s Dan O’Day pulls the plug on the lion’s share of their filgotinib collaboration as the FDA erects a high safety barrier. What went wrong?

5 years ago

Takeda’s gene editing partner is snapped up for $250M cash as sector continues to heat up

5 years ago

Joe Jimenez forges another big-market, small-cash deal, lining up a kidney disease drug for his latest portfolio startup

5 years ago

Eli Lilly picks up gene therapy player Prevail in deal worth $1B+, making good on bolt-on pledge from earlier this year

5 years ago

Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland

5 years ago

Novo Holdings invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics

5 years ago

Chasing Amgen on KRAS combo, Roche dishes out $75M for Relay's SHP2 drug to pair with in-house program

5 years ago

In an end-of-year surprise, AstraZeneca nabs rare disease stalwart Alexion in $39B buyout. But why?

5 years ago

Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+

5 years ago

'Are you guys out of virology?': Not hardly, says Gilead execs, as they buy a late-stage drug company for $1.7B

5 years ago

Peter Thiel's Palantir scores contract with the FDA to speed up regulatory reviews as delays keep growing

5 years ago

Boehringer Ingelheim bags a contract manufacturer, adding muscles for cancer vaccine, oncolytic virus programs

5 years ago

Less than a year after leaving Allergan, Brent Saunders has a $1.1B deal to take his SPAC public

5 years ago

With a potential $458M per target payday, Aligos teams up with Merck hoping to reverse biotech's recent NASH maladies

5 years ago

BioCryst bags $250M in a debt and royalty deal as the executive team preps a new drug launch for HAE

5 years ago

J&J taps the bispecific experts at Xencor for prostate cancer discovery pact, kicking off with $50M upfront

5 years ago

Bayer picks up off-the-shelf CAR-T approach from Atara, spotlighting a Memorial Sloan Kettering breakthrough

5 years ago

Backed by a $200M investment from a Korean conglomerate, Vivek Ramaswamy has quietly built a ‘mother ship’ for vant creation — with a whole new strategy in mind

5 years ago

Merck KGaA bets big on DNA damage upstart, pushing $30M upfront and hefty incentives for a Lynparza pioneer

5 years ago

AbbVie eyes cancer, immunology in latest protein degradation pact, handing Frontier Medicines $55M upfront

5 years ago

J&J buys an early-stage gene therapy for the eye — the only known program for an under-the-radar biotech

5 years ago

AstraZeneca offloads former crown jewel Crestor as it continues to refocus on oncology drugs

5 years ago

Regeneron teams with gene therapy pioneer James Wilson, adapting its Covid-19 antibody cocktail to an AAV-based nasal spray

5 years ago

With aducanumab caught on a cliff, Biogen’s Michel Vounatsos bets billions on another high-risk neuro play

5 years ago

First page Previous page 83 84 858687 88 89 Next page Last page